| Geld/Brief | 22,82 € / 23,50 € |
| Spread | +2,98% |
| Schluss Vortag | 23,29 € |
| Gehandelte Stücke | 1 |
| Tagesvolumen Vortag | 1.090,8 € |
| Tagestief 23,42 € Tageshoch 23,42 € | |
| 52W-Tief 9,982 € 52W-Hoch 29,48 € | |
| Jahrestief 23,29 € Jahreshoch 29,48 € | |
| Umsatz in Mio. | 0,30 $ |
| Operatives Ergebnis (EBIT) in Mio. | -299,04 $ |
| Jahresüberschuss in Mio. | -269,95 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -3,37 $ |
| Gewinnrendite | -40,19% |
| Umsatzrendite | - |
| Return on Investment | -36,36% |
| Marktkapitalisierung in Mio. | 1.535 $ |
| KGV (Kurs/Gewinn) | -5,69 |
| KBV (Kurs/Buchwert) | 2,28 |
| KUV (Kurs/Umsatz) | 4.793 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +90,47% |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 22,68 € | -2,49% | 23,26 € | 09:30 | |
| Frankfurt | 22,71 € | -3,73% | 23,59 € | 08:06 | |
| Stuttgart | 22,83 € | -1,93% | 23,28 € | 11:16 | |
| L&S RT | 23,165 € | -0,45% | 23,27 € | 11:34 | |
| NYSE | 27,47 $ | -2,12% | 28,065 $ | 20.02.26 | |
| Nasdaq | 27,44 $ | -2,31% | 28,09 $ | 20.02.26 | |
| AMEX | 27,84 $ | -0,61% | 28,01 $ | 20.02.26 | |
| Tradegate | 23,42 € | +0,56% | 23,29 € | 09:32 | |
| Quotrix | 23,02 € | -3,88% | 23,95 € | 07:27 | |
| Gettex | 22,83 € | -2,89% | 23,51 € | 11:13 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 20.02.26 | 23,29 | 1.091 |
| 19.02.26 | 23,87 | 0 |
| 18.02.26 | 23,85 | 7.602 |
| 17.02.26 | 23,86 | 24 |
| 16.02.26 | 23,54 | 479 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 23,54 € | +2,97% |
| 1 Monat | 27,85 € | -12,96% |
| 6 Monate | 16,405 € | +47,76% |
| 1 Jahr | 15,60 € | +55,38% |
| 5 Jahre | 14,764 € | +64,18% |
| Marktkapitalisierung | 1,42 Mrd. € |
| Aktienanzahl | 52,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +14,99% | FMR Inc |
| +6,76% | BlackRock Inc |
| +6,59% | Deep Track Capital, LP |
| +5,97% | COMMODORE CAPITAL LP |
| +5,52% | Vanguard Group Inc |
| +5,42% | Kynam Capital Management, LP |
| +4,75% | VR Adviser, LLC |
| +4,24% | Fairmount Funds Management LLC |
| +3,55% | T. Rowe Price Associates, Inc. |
| +3,48% | TANG CAPITAL MANAGEMENT LLC |
| +3,36% | Paradigm Biocapital Advisors LP |
| +3,13% | State Street Corp |
| +2,91% | Novo A/S |
| +2,76% | Maverick Capital Ltd |
| +2,38% | AllianceBernstein L.P. |
| +2,33% | Eversept Partners, LLC |
| +2,14% | Baker Bros Advisors LP |
| +2,13% | Geode Capital Management, LLC |
| +1,64% | Loomis, Sayles & Company LP |
| +1,59% | Parkman Healthcare Partners LLC |
| +14,36% | Weitere |
| 0,00% | Streubesitz |
Zahlen für Q1/21
Company believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024
VRDN-001 and VRDN-002 programs for Thyroid Eye Disease (TED) progressing; on track for IND filings in fourth quarter of 2021
http://investors.miragen.com/press-releases/press-release/2021/Viridian-Therapeutics-Reports-First-Quarter-2021-Financial-Results-and-Provides-Corporate-Updates/default.aspx
